PIK3CA-Related Overgrowth SpectrumSymptoms, Doctors, Treatments, Advances & More
PIK3CA-Related Overgrowth Spectrum Overview
Learn About PIK3CA-Related Overgrowth Spectrum
Sibylle Loibl practices practicing medicine in Neu Isenburg, Germany. Ms. Loibl is rated as an Elite expert by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Breast Cancer in Men, and Mastectomy.
Gustave Roussy
Fabrice Andre practices practicing medicine in Villejuif, France. Mr. Andre is rated as an Elite expert by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Tissue Biopsy, and Mastectomy.
MD Anderson
Funda Meric is a General Surgeon and a Surgical Oncologist practicing medicine in Houston, Texas. Dr. Meric is rated as an Elite provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Breast Cancer, Cholangiocarcinoma (Bile Duct Cancer), Triple-Negative Breast Cancer, and Mastectomy.
Summary: A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).
Summary: The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.


